Understanding and Clarifying the Complexities of HRD Measurements in Cancer

Homologous recombination DNA repair deficiency (HRD) creates a permanent genomic scar in cancer cells for many tumor types. Furthermore, HRD is a response biomarker for poly (ADP-ribose) polymerase inhibitors (PARPi) effective therapy. Consequently, HRD measurement has the potential to improve cancer therapy as evidenced by over 100 clinical trials that include HRD today. However, measuring and standardizing HRD quantitation is not straightforward. HRD measurements may include germline and somatic mutation testing, a measure of hypermethylation, and metrics of genomic instability including loss of heterozygosity, telomeric-allelic imbalance, and large-scale genomic rearrangements. This webinar brings together academic, clinical, IVD, and pharmaceutical experts in the clinical genomics and therapeutics fields to discuss the promises and challenges of HRD measurement for disease management. 

Link